A Novel Indicator Of Lipid Accumulation Product Associated With Metabolic Syndrome In Chinese Children And Adolescents.
childhood obesity
lipid metabolism
metabolic syndrome
Journal
Diabetes, metabolic syndrome and obesity : targets and therapy
ISSN: 1178-7007
Titre abrégé: Diabetes Metab Syndr Obes
Pays: New Zealand
ID NLM: 101515585
Informations de publication
Date de publication:
2019
2019
Historique:
received:
03
07
2019
accepted:
03
09
2019
entrez:
22
10
2019
pubmed:
22
10
2019
medline:
22
10
2019
Statut:
epublish
Résumé
The lipid accumulation product (LAP) is a powerful marker for predicting metabolic syndrome (MS) in adults. The present study aimed to propose a novel indicator, the children's lipid accumulation product (CLAP), and to assess its association with MS among Chinese children and adolescents. A total of 683 Chinese children aged 8-15 years were recruited using a stratified cluster sampling method in this cross-sectional study. The presence of MS was defined according to the NCEP-ATP III criteria. The effects of BMI, WHtR and the CLAP for predicting MS were compared using logistic regression models and receiver operating characteristic (ROC) curves. The prevalence of MS was 5.1% (6.6% and 3.5% among boys and girls, respectively). Overall obesity (based on BMI), abdominal obesity (based on WHtR) and CLAP≥P75 were significantly associated with an increased risk of MS (ORs (95% CIs) were 143.79 (18.78-1101.22), 86.83 (27.19-277.27), 150.75 (20.11-1130.19), respectively). The area under the ROC curve (AUC) for the CLAP was higher than that for BMI and WHtR for predicting MS, with AUC (95% CI) values of 0.944 (0.913-0.975), 0.895 (0.864-0.927), and 0.928 (0.903-0.953), respectively. The children's lipid accumulation product (CLAP) was an effective indicator associated with MS in Chinese children and adolescents and was better than BMI and WHtR for predicting MS.
Sections du résumé
BACKGROUND
BACKGROUND
The lipid accumulation product (LAP) is a powerful marker for predicting metabolic syndrome (MS) in adults. The present study aimed to propose a novel indicator, the children's lipid accumulation product (CLAP), and to assess its association with MS among Chinese children and adolescents.
METHODS
METHODS
A total of 683 Chinese children aged 8-15 years were recruited using a stratified cluster sampling method in this cross-sectional study. The presence of MS was defined according to the NCEP-ATP III criteria. The effects of BMI, WHtR and the CLAP for predicting MS were compared using logistic regression models and receiver operating characteristic (ROC) curves.
RESULTS
RESULTS
The prevalence of MS was 5.1% (6.6% and 3.5% among boys and girls, respectively). Overall obesity (based on BMI), abdominal obesity (based on WHtR) and CLAP≥P75 were significantly associated with an increased risk of MS (ORs (95% CIs) were 143.79 (18.78-1101.22), 86.83 (27.19-277.27), 150.75 (20.11-1130.19), respectively). The area under the ROC curve (AUC) for the CLAP was higher than that for BMI and WHtR for predicting MS, with AUC (95% CI) values of 0.944 (0.913-0.975), 0.895 (0.864-0.927), and 0.928 (0.903-0.953), respectively.
CONCLUSION
CONCLUSIONS
The children's lipid accumulation product (CLAP) was an effective indicator associated with MS in Chinese children and adolescents and was better than BMI and WHtR for predicting MS.
Identifiants
pubmed: 31632117
doi: 10.2147/DMSO.S221786
pii: 221786
pmc: PMC6791402
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2075-2083Informations de copyright
© 2019 Zhang et al.
Déclaration de conflit d'intérêts
All authors gave final approval of the submitted manuscript versions and declare no conflicts of interest in this work.
Références
Pediatr Exerc Sci. 2009 Aug;21(3):339-53
pubmed: 19827457
Int J Obes Relat Metab Disord. 2003 May;27(5):610-6
pubmed: 12704405
Transl Pediatr. 2017 Oct;6(4):397-407
pubmed: 29184820
Sci Rep. 2016 Oct 26;6:36091
pubmed: 27782221
Diabetes Care. 2011 Jun;34(6):1323-8
pubmed: 21505206
J Clin Invest. 2015 Feb;125(2):478-86
pubmed: 25642708
Zhonghua Liu Xing Bing Xue Za Zhi. 2015 Aug;36(8):884-8
pubmed: 26714549
J Pediatr Endocrinol Metab. 2013;26(11-12):1123-30
pubmed: 23751385
BMC Cardiovasc Disord. 2005 Sep 08;5:26
pubmed: 16150143
Nutrients. 2016 Oct 01;8(10):
pubmed: 27706073
Nutr Hosp. 2013 Nov 01;28(6):1951-60
pubmed: 24506374
Int J Endocrinol. 2014;2014:195407
pubmed: 25574166
Obes Rev. 2015 Jan;16(1):1-12
pubmed: 25407540
BMC Pediatr. 2014 Feb 14;14:42
pubmed: 24529305
Clin Endocrinol (Oxf). 2014 Jul;81(1):45-51
pubmed: 23746346
Int J Environ Res Public Health. 2016 Jun 14;13(6):
pubmed: 27314368
J Am Diet Assoc. 2008 Feb;108(2):276-86; discussion 286
pubmed: 18237576
PLoS One. 2015 Oct 13;10(10):e0139984
pubmed: 26461112
Curr Hypertens Rep. 2014 Jul;16(7):449
pubmed: 24819559
J Clin Endocrinol Metab. 2014 Sep;99(9):3208-16
pubmed: 24926951
Zhonghua Yu Fang Yi Xue Za Zhi. 2017 Apr 6;51(4):295-299
pubmed: 28395461
PLoS One. 2013;8(2):e56159
pubmed: 23418529
Int J Nurs Pract. 2015 Apr;21(2):175-83
pubmed: 24666551
Pediatr Gastroenterol Hepatol Nutr. 2016 Sep;19(3):199-206
pubmed: 27738602
Metab Syndr Relat Disord. 2014 Dec;12(10):527-32
pubmed: 25247821
Zhonghua Liu Xing Bing Xue Za Zhi. 2004 Feb;25(2):97-102
pubmed: 15132858
Metab Syndr Relat Disord. 2018 Jun;16(5):240-245
pubmed: 29648916
Curr Opin Clin Nutr Metab Care. 2015 Nov;18(6):535-51
pubmed: 26335310
Pediatrics. 2008 Jul;122(1):198-208
pubmed: 18596007
Arch Pediatr Adolesc Med. 2003 Aug;157(8):821-7
pubmed: 12912790
J Res Med Sci. 2016 Oct 18;21:90
pubmed: 28163736
Obes Rev. 2014 Jan;15 Suppl 1:37-48
pubmed: 24341757
Eur J Endocrinol. 2011 Apr;164(4):559-67
pubmed: 21262912
BMC Public Health. 2017 Jun 26;17(1):598
pubmed: 28651555
Zhonghua Er Ke Za Zhi. 2013 Jun;51(6):409-13
pubmed: 24120056
Am J Hum Biol. 2017 Nov;29(6):null
pubmed: 28667803
PLoS One. 2016 Jan 08;11(1):e0146579
pubmed: 26745148